Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 72

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer stage III+3

Not recruiting

Study on Preoperative Treatment for HER2 Positive Breast Cancer Using Docetaxel, Pertuzumab, and Trastuzumab in Patients with Primary Breast Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Karolinska University Hospital

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Lichen sclerosus

Not recruiting

Study on the Effectiveness and Safety of MC2-25 Cream for Women with Vulvar Lichen Sclerosus

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alanyl Glutamine
  • Sponsor:Mc2 Therapeutics Limited

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Endometrial cancer

Not recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer metastatic+2

Not recruiting

Study of Patritumab Deruxtecan for Patients with Brain Metastases from Advanced Breast or Lung Cancer and Leptomeningeal Disease from Solid Tumors

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Medica Scientia Innovation Research S.L.

Infertility

Not recruiting

Study on Infertility: Comparing Corifollitropin Alfa and Follitropin Beta for Women Undergoing Elective Fertility Preservation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Corifollitropin Alfa
  • Sponsor:Santiago Dexeus Font Fundacio Privada

Triple negative breast cancer

Not recruiting

Study on the Effects and Safety of PLX038 for Patients with Advanced or Metastatic Triple-Negative Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Peg-7-Ethyl-10-Hydroxycamptothecin
  • Sponsor:Institut Curie

Endometrial cancer+6

Not recruiting

Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Anastrozole
  • Sponsor:University Of Florence

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Doxorubicin
  • Sponsor:Merck Sharp & Dohme LLC

Hormone-refractory prostate cancer

Not recruiting

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.